FIGURE 2

FIGURE 2

Huanglian Jiedu decoction (HLJDD) and its three major components alleviated the mRNA expression of the key mediators and inflammatory cytokines. (A) HLJDD and its three major components could inhibit lipopolysaccharide (LPS)-induced inflammation by ameliorating the mRNA expression of MyD88, p65, IκB-α, ERK, JNK, and p38 controlled by the TLR4/MyD88 pathway. (B) HLJDD and its three major components ameliorated IL-6, IL-1β, TNF-α, IL-10, and IFN-γ to return to normal level. ^∗P < 0.05, ^∗∗P < 0.01, and ^∗∗∗P < 0.001, four drug treatment groups compared to the LPS group. ^###P < 0.001, LPS group compared to the control group. MyD88: Binding Toll-like Receptor. p65: Response to cytokine. IκB-α: Negative regulation of NF-κB transcription factor activity. ERK, JNK, p38: Activation of MAPK activity. IL-6, IL-1β, TNF-α, IL-10, IFN-γ: Regulation of inflammatory response.